#United States #San Diego #Neuroscience #Resonant #Methylation

Resonant Announces Key Presentation at SfN Annual Meeting

Resonant, a cutting-edge biotechnology enterprise specializing in molecular diagnostics, is slated to showcase its pioneering native methylation sequencing technology at the upcoming Society for Neuroscience (SfN) Annual Meeting, taking place from November 15 to 19, 2025, in San Diego, California. This event, which attracts neuroscientists from around the globe, serves as a platform for the dissemination of groundbreaking research, and Resonant's presentation is expected to draw considerable attention.

Innovative Approach to Neurodegenerative Disease Detection

The focal point of Resonant’s presentation is the session titled "Native Methylation Sequencing for Detection and Monitoring of Alzheimer's Disease, Parkinson's and Other Neurodegenerative Conditions." Dr. Chad Pollard, Resonant’s CEO, will lead the discussion, scheduled for November 16 at 11:15 AM. The company's research aims to enhance the diagnostics of complex neurological disorders by employing a non-invasive blood test that analyzes neuron-specific methylation patterns in circulating cell-free DNA (cfDNA).

This innovative method promises to provide earlier and more accurate diagnostic insights for neurodegenerative diseases, which have traditionally posed significant challenges in clinical settings. By recognizing specific methylation signatures associated with different neuron types, Resonant hopes to establish a more definitive link between cfDNA levels and neuronal deterioration, paving the way for early detection and monitoring of conditions like Alzheimer's and Parkinson's disease.

Research Outcomes: A Closer Look at Methylation Profiling

During the presentation, Resonant will present compelling data drawn from a cohort of 219 patient blood samples. Their findings highlight the capacity of neuron-derived cfDNA to effectively differentiate between various neurodegenerative diseases and healthy controls. Notably, they demonstrated that specific methylation signatures for cortical neurons (indicative of Alzheimer's), dopaminergic neurons (pertinent to Parkinson’s), and spinal motor neurons (linked to amyotrophic lateral sclerosis, ALS) could be clearly distinguished from one another.

The research employed a sophisticated multivariate classifier that incorporated all three neuron-derived cfDNA signatures, achieving remarkable results in discrimination performance. The area under the curve (AUC) measurements indicated an impressive distinction:

• - Cortical (Alzheimer's): AUC = 1.0000 (95% CI 1.0000–1.0000)
• - Dopaminergic (Parkinson's): AUC = 0.9851 (95% CI 0.9688–1.0000)
• - Spinal motor (ALS): AUC = 0.9905 (95% CI 0.9753–1.0000)

These statistical outcomes underscore the profound potential of cfDNA methylation profiling as a viable liquid biopsy tool, capable of facilitating early detection, continuous monitoring, and therapeutic evaluation across a spectrum of neurodegenerative disorders.

About Resonant

Founded with the mission to elevate the field of neurobiology through advanced technology, Resonant is at the forefront of leveraging native methylation sequencing techniques. This innovative strategy enables researchers to obtain real-time insights into cellular dynamics and disease progression, ultimately aiming to enrich clinical research and therapeutic decision-making.

Interested parties are encouraged to visit Resonant’s booth (#3210) at the SfN Annual Meeting or connect digitally through their official website. For more updates on probing the intricacies of neurodegeneration and the role of methylation sequencing, visit their platform at Resonant or follow them on LinkedIn.

By participating in discussions around such a crucial area of neuroscience, Resonant positions itself as a pioneer in transforming the landscape of neurological diagnostics, potentially setting new standards for the early identification and management of debilitating brain disorders.